Does an orphan drug policy make a difference in access? A comparison of Canada and Australia.

2 January 2020 - Canada has been discussing whether to implement an orphan drug policy for more than 25 years. Recently, ...

Read more →

Akcea and Ionis announce acceptance of marketing applications in US, EU and Canada for volanesorsen for the treatment of FCS

15 November 2017 - FDA Prescription Drug User Fee Act goal date set for 30 August 2018. ...

Read more →

Health Canada gives 'kiss of death' to planned policy for rare-disease drugs

16 October 2017 - The framework was announced by the Harper government in 2012, but sat on the back burner since ...

Read more →

Amicus Therapeutics announces approval for Galafold (migalastat) for treatment of Fabry disease in Canada

14 September 2017 - First oral precision medicine for Fabry disease with broad label for Fabry patients with amenable genetic ...

Read more →

Sanofi Genzyme announces approval of Cerdelga (eliglustat tartrate) by Health Canada for rare genetic condition

1 May 2017 - Sanofi Genzyme announced today that Health Canada has recently approved Cerdelga (eliglustat capsules), the only first-line ...

Read more →